Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract

H. Kantarjian; J. A. Ajani; D. A. Karlin

doi:10.1159/000226003

Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract

H. Kantarjian, J. A. Ajani, D. A. Karlin

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m² i.v. over 2 h every 3-4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.

Original language	English (US)
Pages (from-to)	69-71
Number of pages	3
Journal	Oncology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1159/000226003
State	Published - 1985
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1159/000226003

Cite this

@article{8a4e51b87b9143fb855c068b4915541a,

title = "Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract",

abstract = "A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m2 i.v. over 2 h every 3-4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.",

author = "H. Kantarjian and Ajani, {J. A.} and Karlin, {D. A.}",

year = "1985",

doi = "10.1159/000226003",

language = "English (US)",

volume = "42",

pages = "69--71",

journal = "Oncology",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "2",

}

TY - JOUR

T1 - Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract

AU - Kantarjian, H.

AU - Ajani, J. A.

AU - Karlin, D. A.

PY - 1985

Y1 - 1985

N2 - A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m2 i.v. over 2 h every 3-4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.

AB - A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m2 i.v. over 2 h every 3-4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.

UR - http://www.scopus.com/inward/record.url?scp=0021912626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021912626&partnerID=8YFLogxK

U2 - 10.1159/000226003

DO - 10.1159/000226003

M3 - Article

C2 - 3921891

AN - SCOPUS:0021912626

SN - 0030-2414

VL - 42

SP - 69

EP - 71

JO - Oncology

JF - Oncology

IS - 2

ER -

Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this